These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32698955)

  • 1. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
    Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
    Edderkaoui M; Chheda C; Soufi B; Zayou F; Hu RW; Ramanujan VK; Pan X; Boros LG; Tajbakhsh J; Madhav A; Bhowmick NA; Wang Q; Lewis M; Tuli R; Habtezion A; Murali R; Pandol SJ
    Gastroenterology; 2018 Dec; 155(6):1985-1998.e5. PubMed ID: 30144430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
    Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
    Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
    Wang H; Luo Y; Qiao T; Wu Z; Huang Z
    J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
    Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
    J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
    Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
    Molecules; 2017 May; 22(5):. PubMed ID: 28467373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
    J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
    Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
    Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.